Elevated C-met in Thymic Dendritic Cells of New Zealand Black Mice by Okada, Tomoyuki et al.
Elevated C-met in Thymic Dendritic Cells of New Zealand
Black Mice
TOMOYUKI OKADA
a,b, ZHE-XIONG LIAN
a, TOM HSU
a, MITSURU NAIKI
b, AFTAB A. ANSARI
c, DAN ROBINSON
d,
HSING-JIEN KUNG
d, RICHARD BOYD
e and M. ERIC GERSHWIN
a,*
aDivisionof Rheumatology/Allergyand ClinicalImmunology, Universityof Californiaat DavisSchoolof Medicine,TB192,OneShields Avenue, Davis,
CA 95616, USA;
bInstitute of Bio-Active Science, Nippon Zoki Pharmaceutical Co. Ltd., Kinashi, Yashiro-Cho, Kato-gun, Hyogo 673-1461, Japan;
cDepartment of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA;
dBasic Science Research, UC Davis School of Medicine,
UC Davis Cancer Center, Sacramento, California, CA 95817, USA;
eDepartment of Microbiology and Immunology, Monash University, Victoria,
Australia
New Zealand Black (NZB) mice are a well-known animal model of human autoimmune disease.
Although the mechanism for development of autoimmunity is unclear, NZB mice are well known for
severe thymic microarchitecture abnormalities. It is thought that thymic dendritic cells (DC) may play a
role in thymic education and contribute to the autoimmune process. To address this issue and, in
particular, that qualitative and/or quantitative differences exist in thymic DC, we took advantage of a
novel restriction analysis system that allow deﬁnition of differences in the expression of tyrosine
kinases using highly enriched populations of thymic DC from NZB compared to BALB/c and C57BL/6
mice. The method chosen, restriction analysis of gene expression, allowed the determination of protein
tyrosine kinase transcription proﬁles. We report herein that NZB mice have a signiﬁcant upregulation of
C-met compared to the control strains. The abnormality of the C-met transcription was conﬁned to
thymic DC. We believe that its abnormal expression reﬂects the resistance of thymic cells to apoptosis,
which will ultimately lead to defects and/or abnormal signaling by the interaction of thymic DC and
thymocytes. Further studies involving such interactions are under way.
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INTRODUCTION
The New Zealand Black (NZB) mouse develops an auto-
immune disease characterized by high serum IgM levels
and autoantibody production that progresses with age
(Borchers et al., 2000). Recently our laboratories have
shown abnormalities in thymic microarchitecture invol-
ving epithelial cell network (Watanabe et al., 1993;
Takeoka et al., 1999) and thymic B cells (Taguchi et al.,
2001a,b) in the NZB mouse. The mechanisms for these
changes and the relationship to autoimmunity are
unknown.
Thymic dendritic cells (DC) originate from the bone
marrow and reside within the thymic medulla or at the
cortico-medullary junction (Ardavin, 1997) and play a
pivotal role in thymocyte education, particularly in the
context of negative selection (Anderson et al., 1996;
Brocker et al., 1997; Ferrero et al., 1997; Brocker, 1999).
It has been previously shown that this process of negative/
positive selection is, to a large extent, mediated by signals
generated intracellularly following lymphoid cell surface
interaction with corresponding ligands expressed by cells
involved in the selection process, which includes thymic
DC. We hypothesized that qualitative and/or quantitative
differences may exist in the ability of thymic DC to
mediate T cell selection in NZB mice which would
contribute to the autoimmune disease in such mice. The
recent description of a novel restriction analysis of gene
expression (RAGE) (Robinson et al., 1996; Lin et al.,
2000), which can be performed on small numbers of cells,
prompted us to use this technique for deﬁning differences
(if any) in the expression of tyrosine kinases by highly
enriched populations of thymic DC from NZB as
compared to BALB/c and C57BL/6 mice. The tyrosine
kinases were chosen based on an extensive body of data
that indicates the importance of such kinases as regulators
of intracellular signal-transduction mediating molecules
and the mediation of intracellular communication
(Blume-Jensen and Hunter, 2001).
We report herein a marked selective thymic DC up-
regulation of C-met tyrosine kinase mRNA in NZB mice.
This is the ﬁrst report of an abnormal transcription of a
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cell–cell adhesion within the NZB thymus. These
abnormalities may result in the escape of autoimmune T
cells, with development of the resulting disease
phenotype.
MATERIALS AND METHODS
Mice
BALB/cJ, C57BL/6J, and NZB/BINJ mice were obtained
from the Jackson Laboratory (Bar Harbor, ME) and bred at
the Animal Resource Services Facility at the University of
California, Davis. Four to ﬁve weeks-old mice were used
for these experiments.
Antibodies and Reagents
FITC-conjugated rat anti-mouse MHC class II (M5/
114.15.2) antibody was purchased from Miltenyi Biotec
(Auburn, CA). FITC-conjugated rat anti-mouse CD8a
(53-6.7), PE-conjugated hamster anti-mouse CD11c
(HL3), FITC and a series of biotin-conjugated rat
anti-mouse CD45R/B220 (RA3-6B2), hamster anti-mouse
CD80 (16-10A1), rat anti-mouse CD86 (GL1), rat
anti-mouse CD40 (3/23) antibodies were each purchased
fromBDBioscience(SanDiego,CA).Tricolorconjugated
streptavidin and anti-mouse CD16/32 antibody were
purchased from Caltag laboratories (Burlingame, CA).
Thymic DC Enrichment
Thymii of mice were subjected to digestion by incubation
for 15min at 378C in Hank’s balanced salt solution
(HBSS) containing 60 units/ml collagenase IV (Sigma,
St. Louis, MO) and 25k units/ml deoxyribonuclease
I (Sigma) and 0.2% bovine serum albumin (BSA). The
resulting population of cells were ﬁltered through a
100mm mesh, collected by centrifugation at 300g for
5min, and washed with PBS containing 0.2% BSA and
5mM EDTA. After centrifugation, the cell pellets were
resuspended in 17% Optiprepe (Nycomed Pharma, Oslo,
Norway) solution diluted with HBSS (containing 0.2%
BSA and 5mM EDTA) and underlaid in a solution of 12%
Optiprepe in PBS (with 0.2% BSA and 5mM EDTA)
and HBSS (with 0.2% BSA and 5mM EDTA). The
gradient was centrifuged at 600g for 15min at 208C.
The low density cells at the HBSS/12% Optiprepe
solution interface were collected, resuspended in PBS
(containing 0.2% BSA and 5mM EDTA), and recovered
by centrifugation.
Flow Cytometry and Thymic DC Isolation
In efforts to deﬁne the frequency and phenotype of the
enriched thymic DC, an aliquot of the cell suspension was
stained with PE-conjugated anti-mouse CD11c mAb,
FITC or biotin-conjugated anti-mouse B220 mAb, and
FITC conjugated anti-mouse MHC class II, FITC
conjugated anti-mouse CD8a, biotin conjugated anti-
mouse CD80 (B7.1), biotin conjugated anti-mouse CD86
(B7.2), or biotin conjugated anti-mouse CD40. Biotiny-
lated antibodies were visualized using tricolor streptavi-
din. Prior to staining, the FcgII/III receptor on cells were
blocked by preincubation of the samples with an anti-
mouse CD16/32 antibody to reduce non-speciﬁc staining.
Cells were incubated with primary antibodies in staining
buffer (0.2% BSA and 0.1% NaN3 in PBS) for 30min at
48C, washed in washing buffer (0.2% BSA and 5mM
EDTA in PBS), and incubated with tricolor streptavidin in
staining buffer for an additional 30min at 48C. After the
last wash, the cells were resuspended in washing buffer
and viable cells from each sample were analyzed using
ﬂow cytometry (FACScan, BD) and the data analyzed
using Cell Quest software (BD). To isolate thymic DC,
thymic CD11c
þB220
2 MHC classII
high cells from DC-
enriched preparation were collected by 10-parameter
MoFlo cell sorter (Cytomation, Fort Collins, CO)
equipped with Summit software. The frequency of thymic
DC was always .95% in the preparations utilized for the
studies reported herein.
Splenic DC Isolation
Splenic DC enrichment was performed essentially as
described above for thymic DC enrichment. Splenic DC
were treated with rat anti-mouse B220 mAb followed by
incubation with sheep anti-rat IgG-conjugated magnetic-
beads (Dynal, Oslo, Norway). Passage through a magnetic
ﬁeld was used to deplete the B220
þ cells. Such enriched
splenic B220
2 cells were subsequently incubated with
CD11c microbeads (Miltenyi Biotec) and the CD11c
þ
cells isolated and subjected to further enrichment using a
cellsorter.ThefrequencyofsplenicDCwasalways.90%
for the assays utilized in the studies reported herein.
RNA Extraction and cDNAs Synthesis
Total RNA was extracted from splenic and thymic DC
from BALB/c, C57BL/6, and NZB mice utilizing the
RNeasy kit (QIAGEN, Valencia, CA), cDNAs were
synthesized using Superscripte II (Life Technologies,
Grand Island, NY) and oligo dT(12–18) primer (Life
Technologies).
RAGE Analysis for Tyrosine Kinases
The RAGE assay was carried out using a modiﬁcation of
the method previously described (Lee et al., 1999).
Essentially, reverse transcription-polymerase chain
reaction (RT-PCR) was performed with degenerate
primers derived from conserved motifs in the activation
loop of the catalytic domains of various tyrosine kinases
as follows: primer 1 (sense primer), 50-AAR RTT DCN
GAY TTY GG encoding the amino acid sequence
T. OKADA et al. 30K[V/I][S/C/G]DFG; primer 2 (antisense primer), 50-RHA
IGM CCA IAC RTC encoding the amino acid sequence
DVW[S/A][F/Y]. The mixed bases were deﬁned as
follows: N ¼ A þ C þ T þ G, D ¼ A þ T þ G,
H ¼ A þ T þ C, R ¼ A þ G, Y ¼ C þ T, M ¼ A þ C,
and I ¼ deoxyinosine. Primer 1 was labeled with [g-
33P]
ATP (NEN Life Science Products, Boston, MA) and T4
polynucleotide kinase (Life Technologies) and PCR was
performed by using
33P labeled primer1, unlabeled
primer2, and AmpliTaq Gold DNA polymerase (Perkin–
Elmer, Boston, MA). The PCR products were electro-
phoresed in a 2.4% agarose gel (3:1 ratio of Nusieve
GTG and regular agarose; BMA, Rockland, ME). The
153–177bp bands were excised from the gel and DNA
eluted using the QIAEXII gel extraction kit (QIAGEN).
Samples were standardized by adjustments based on
radioactivity as determined by radioactive scintillation.
Equal amounts of radioactive DNA of each sample were
digested with AciI, AluI, AvaII, BsrI, DdeI, HaeIII, HinfI,
HpaII, MnlI, RsaI, or Taq
a I restriction enzyme (New
England Biolabs, Beverly, MA) resolved on a 7% DNA
sequencing gel, and exposed overnight at 2708Co na
ﬂuorescent screen for quantitative analysis on a Phos-
phoimager
w (Molecular Dynamics, Sunnyvale, CA).
RT-PCR
Serial dilutions of cDNA were PCR-ampliﬁed for c-met,
Bcl-XL,o rb-actin usingAmpliTaq Gold DNA polymerase
in the presence of either c-met primers (50-CCA GCA
GCT TCA GTT ACC GG-30,5 0-GCG ATG CTG ACA
TGC CAC TG-30) Bcl-XL primer (50-TGA TTC CCA TGC
CAG CAG TGA-30,5 0-AAC CAC ACC AGC CAC AGT
CAT-30), or b-actin primer (50-CCT AAG GCC AAC
CGT GAAAAG-30,5 0-TCT TCA TGG TGC TAG GAG
CCA-30). Ampliﬁed products (c-met 182bp, Bcl-XL
434bp, b-Actin 646bp) were electrophoresed on a 1.5%
agarose gel and visualized with ethidium bromide. In these
studies the c-met primers were designed using Primer
Express 1.0 software (Applied Biosystems, Foster, CA).
In addition, the resulting PCR product of 182bp which
corresponds to the expected c-met mRNA-derived signals,
was conﬁrmed to be the c-met gene by direct sequencing
of the PCR product.
Real-Time PCR
Analysis was performed using the GeneAmp 5700
Sequence Detection system (Perkin–Elmer) utilizing
SYBReGreen (Molecular Probes,Eugene, OR) as descri-
bed (Taguchi et al., 2001a). Primers for c-met were the
same as used in the RT-PCR experiment. b-actin primers
(50-ACT ATT GGC AAC GAG CGG TT-30,5 0-CAG GAT
TCC ATA CCC AAG AAG GA-30) were designed using
Primer Express 1.0 software (Perkin–Elmer). Standard
curves were generated using diluted cDNA of thymic
CD11c
þ cells for c-met or b-actin. To measure relative
intensity between normal and NZB mice, the ratio of
c-met mRNA level was calculated as c-met intensity
divided by b-actin intensity. All reaction wells were run in
duplicate and included control wells without cDNA.
RESULTS
Thymic Dendritic Cell Frequency in NZB Mice
Thymii from groups of NZB and for purposes of control,
BALB/c and C57BL/6 mice were individually analyzed
for the frequency of thymic DC (mean ^ SEM).
The NZB thymic DC frequency (mean ^ SEM)
(4:07 ^ 0:45 £ 104=108 total thymocytes) was similar to
that of control mice (BALB/c; 3:39 ^ 0:36 £ 104=108;
C57BL/6; 4:08 ^ 0:35 £ 104=108 total thymocytes). The
level of expression of cell surface markers in NZB thymic
DC was not signiﬁcantly different from control thymic DC
(MHC II
high, CD8a
þ, CD40
þ, B7.1
þ, B7.2
þ, data not
shown).
Determination of Protein Tyrosine Kinase
Transcription Proﬁle in NZB Thymic DC
We next carried out studies to document the proﬁle of
tyrosine kinase utilizing the RAGE assay expressed by
highly enriched populations of one month old BALB/c
and NZB thymic DC (CD11c
þB220
2 cells). Ampliﬁed
PCR products containing a series of tyrosine kinases were
digested with the restriction enzymes and the intensity of
bands compared. Repeated analysis of visualized bands
led to the identiﬁcation of three bands which had higher
signal intensity in NZB thymic DC. Based on the associa-
tion between the restriction enzyme used and the length of
band obtained, the BsrI digested 92bp band corresponded
to the Frk, C-met, and/or, Ron tyrosine kinases (Fig. 1a).
The HinfI digest led to a 115bp band which was identiﬁed
to be C-met tyrosine kinase (Fig. 1b). The RsaI digested
44bp band corresponded to Ddr2, C-met, and/or Trk-B
tyrosine kinases (Fig. 1c). Thus, C-met kinase appeared to
be the common tyrosine kinase identiﬁed by these restric-
tion enzyme digests.
Identiﬁcation of PTK mRNA that are Differentially
Expressed by NZB Thymic DC
In efforts to conﬁrm the above difference in c-met at the
mRNA level, RT-PCR analysis was performed using
c-met speciﬁc primers. Figure 2a shows that the c-met
mRNA level in NZB thymic DC was higher than control
strains. To improve sensitivity and quantitation, real-time
PCR was performed which included the b-actin primers.
As seen in Fig. 2b, NZB thymic DC contained a higher
level of c-met mRNA. Thus, the RT-PCR and real time
PCR data concur with the RAGE data and clearly
demonstrates that c-met mRNA levels in NZB thymic DC
is higher than control mice.
THYMIC DENDRITIC CELLS AND NZB MICE 31c-met mRNA by Thymocytes and Splenic DC
To ascertain the lineage speciﬁcity of the increased
expression of c-met mRNA, a comparative analysis of
c-met mRNA levels was carried out on total thymocytes
and splenic DC by real time-PCR. Interestingly, thymo-
cytes from control mice and NZB mice had a much lower
c-met mRNA level (Fig. 3) than corresponding thymic
DC. In addition, it was of interest to note that the c-met
mRNAlevelinNZBsplenicDCwassimilartocontrolthy-
mic and splenic DC. These data suggest that the abnormal
expression on c-met mRNA is restricted to the population
of NZB thymic DC and not a global dysregulation of c-met
expression.
BCl-XL mRNA Level in NZB Thymic DC
Previous reports have shown that the interaction of HGF
and c-met leads to the induction of resistance to apoptotic
cell death (Xiao et al., 2001). To clarify the relationship
between c-met upregulation of NZB thymic DC and
apoptotic resistance, we examined the mRNA levels of
BCl-XL, an anti-apoptotic factor, in thymic DC by using
RT-PCR. As expected, the BCl-XL mRNA level was
higher in NZB thymic DC than in control mice (Fig. 4).
These data suggest that c-met may function as an integral
participant in the anti-apoptotic cascade.
DISCUSSION
In systemic lupus erythematosus (SLE) patients, the Fyn
tyrosine kinase activity of T cells from peripheral blood
has been shown to be elevated when compared to healthy
donors (Blasini et al., 1998). Using a variety of tyrosine
kinase family of mutated or knockout mice, it was
reported that such tyrosine kinases are involved in the
development of SLE like disease (Morino et al., 1999; Lu
FIGURE 1 Comparison of PTK proﬁle between BALB/c and NZB thymic DC. Sorted thymic CD11
þB220
2 derived cDNA from BALB/c and NZB
mice were ampliﬁed using tyrosine kinase primers and digested with BsrI (a), HinfI (b), and RsaI (c). Digested PCR products were electrophoresed and
compared with regards to intensity. (a), (b), and (c) showed that c-met mRNA may be higher in NZB thymic DC.
FIGURE2 Identiﬁcation of PTK mRNA levelsin NZB thymicDC. (a) Seriallydiluted thymicCD11c
þB220
2 derived cDNA from BALB/c, C57BL/6,
and NZB mouse were ampliﬁed using c-met or b-actin speciﬁc primers, electrophoresed, and visualized with ethidium bromide. Intensity of the c-met
band was higher in NZB thymic DC. (b) Thymic CD11c
þB220
2 derivedcDNA from BALB/c, C57BL/6,and NZB mouse were ampliﬁed using c-met or
b-actin speciﬁc primers, and visualized with SYBRe Green by real time-PCR. Standard curves were generated using diluted cDNA of thymic CD11c
þ
cells for c-met or b-actin. To measure relative intensity between normal and NZB mice, the ratio of c-met mRNA level was calculated as c-met intensity
divided by b-actin intensity.
T. OKADA et al. 32and Lemke, 2001; Yu et al., 2001). These data provided
the basis for our rationale to screen for all ampliﬁed
tyrosine kinases in efforts to identify the spectrum of
tyrosine kinases that maybe potentially dysregulated in
autoimmune prone NZB mice as compared with normal
BALB/c and C57BL/6 mice.
C-met kinase is a receptor for the hepatocyte growth
factor (HGF) and its gene has been localized to mouse
chromosome 6 (Chan et al., 1988). C-met is expressed
within a number of cell lineages, including epithelial cells
(Di Renzo et al., 1991), endothelial cells (Bussolino et al.,
1992), myoblasts (Anastasi et al., 1997), and hemato-
poietic cells (Galimi et al., 1994; Nishino et al., 1995).
Interaction of HGF with c-met activates multiple
intracellular signaling pathways involved in muscle and
liver formation (Schmidt et al., 1995; Maina et al., 1996),
cell proliferation, morphogenesis, and motility. In contrast
to thymic DC, c-met mRNA levels in NZB splenic
DC was similar to control splenic DC, suggesting that
either the elevation of c-met mRNA levels in NZB
thymic DC might be independent of a defect of the entire
NZB DC population, or thymic DC may comprise a
sublineage of DC with unique homing properties to the
thymus.
It is unknown why the c-met transcription abnormality
is conﬁned to the thymic DC population in NZB mice.
Among the potential reasons entertained is our previously
documented thymic architectural abnormalities in NZB
mice (Watanabe et al., 1993; Takeoka et al., 1999).
HGF/c-met interaction exerts an upregulation of anti-
apoptotic related genes (Aebersold et al., 2001) and
downregulation of E-cadherin (Miura et al., 2001) and
adhesion molecules, mediated by b-catenin (Behrens
et al., 1993; Danilkovitch-Miagkova et al., 2001). From
our data, the anti-apoptotic factor, Bcl-XL mRNA in NZB
thymic DC was signiﬁcantly higher than control strains of
mice. C-met upregulation in thymic DC may contribute to
resistance against apoptosis. It is reasoned that the
elevation of c-met in NZB thymic DC causes a decrease in
the levels of E-cadherin, which leads to defects and/or
abnormal signaling by the interaction between thymic DC
and thymocytes. It is of interest to note that signiﬁcant
levels of c-met have been documented to be expressed by
fetal thymus, liver and hematopoietic cells (Selden et al.,
1990; Hu et al., 1993; Galimi et al., 1994; Tamura et al.,
1998) but to a lower level by adult thymic and splenic DC
in normal mice. Preliminary studies of highly enriched
populations of adult thymic CD3
2CD4
2CD8
2 cells
(triple negative thymocytes also known as progenitors
for T cells and DC) also expressed signiﬁcantly higher
levels of c-met than adult thymocytes (data not shown).
These data support the concept that c-met expression may
be a marker of immature cells. Thus, such immature NZB
thymic DC may not optimally function in the deletion of
autoreactive T cells.
FIGURE 3 C-met mRNA level on thymocytes and splenic DC. Total thymocytes (BALB/c, C57BL/6, and NZB mouse), splenic DC (BALB/c,
C57BL/6, and NZB mouse), and thymic DC (BALB/c and NZB mouse) cDNAwere ampliﬁed by the speciﬁc primers c-met or b-actin using real-time
PCR.
FIGURE 4 Bcl-XL mRNA is higher in NZB thymic DC. Serially diluted
thymic CD11c
þB220
2 derived cDNA from BALB/c, C57BL/6, and
NZB mice were ampliﬁed using Bcl-XL or b-actin speciﬁc primer,
electrophoresed, and visualized with ethidium bromide. b-actin band
intensity replicated the dilution results. The intensity of Bcl-XL band was
higher in NZB than BALB/c and C57BL/6 thymic DC. Note the intensity
of signaling in the NZB sample at 1/5 cDNA dilution, as compared to the
lack of expression in control mouse at the same dilution.
THYMIC DENDRITIC CELLS AND NZB MICE 33It would be important to conﬁrm the relative levels of
RNAwithlevelsofc-metproteinexpression.However,this
could not be examined on thymic DC because it was
difﬁcult to collect enough cells to carry out such studies.
In addition, in efforts to clarify the mechanism of c-met
elevationbyNZBthymicDC,astudyofHGFandadhesion
molecules should be performed. Finally, since the data
described herein imply the potential of a growth arrest
of thymic DC progenitor cells which may be a source of
abnormalities in the NZB mouse, they will be closely
examined in the context of c-met in future experiments.
References
Aebersold, D.M., Kollar, A., Beer, K.T., Laissue, J., Greiner, R.H. and
Djonov, V. (2001) “Involvement of the hepatocyte growth factor/
scatter factor receptor c-met and of Bcl-XL in the resistance of
oropharyngealcancertoionizingradiation”,Int.J.Cancer96,41–54.
Anastasi, S., Giordano, S., Sthandier, O., Gambarotta, G., Maione, R.,
Comoglio, P. and Amati, P. (1997) “A natural hepatocyte growth
factor/scatter factor autocrine loop in myoblast cells and the effect of
the constitutive Met kinase activation on myogenic differentiation”,
J. Cell Biol. 137, 1057–1068.
Anderson, G., Moore, N.C., Owen, J.J. and Jenkinson, E.J. (1996)
“Cellular interactions in thymocyte development”, Annu. Rev.
Immunol. 14, 73–99.
Ardavin, C. (1997) “Thymic dendritic cells”, Immunol. Today 18,
350–361.
Behrens, J., Vakaet, L., Friis, R., Winterhager, E., Van Roy, F., Mareel,
M.M. and Birchmeier, W. (1993) “Loss of epithelial differentiation
and gain of invasiveness correlates with tyrosine phosphorylation of
the E-cadherin/beta-catenin complex in cells transformed with a
temperature-sensitive v-SRC gene”, J. Cell Biol. 120, 757–766.
Blasini, A.M., Brundula, V., Paris, M., Rivas, L., Salazar, S., Stekman,
I.L. and Rodriguez, M.A. (1998) “Protein tyrosine kinase activity in
T lymphocytes from patients with systemic lupus erythematosus”,
J. Autoimmun. 11, 387–393.
Blume-Jensen, P. and Hunter, T. (2001) “Oncogenic kinase signalling”,
Nature 411, 355–365.
Borchers, A., Ansari, A.A., Hsu, T., Kono, D.H. and Gershwin, M.E.
(2000) “The pathogenesis of autoimmunity in New Zealand mice”,
Semin. Arthritis Rheum. 29, 385–399.
Brocker, T. (1999) “The role of dendritic cells in T cell selection and
survival”, J. Leukoc. Biol. 66, 331–335.
Brocker, T., Riedinger, M. and Karjalainen, K. (1997) “Targeted
expression of major histocompatibility complex (MHC) class II
moleculesdemonstratesthatdendriticcellscaninducenegativebutnot
positive selectionof thymocytes invivo”, J.Exp. Med.185, 541–550.
Bussolino, F., Di Renzo, M.F., Ziche, M., Bocchietto, E., Olivero, M.,
Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A. and Comoglio,
P.M. (1992) “Hepatocyte growth factor is a potent angiogenic factor
which stimulates endothelial cell motility and growth”, J. Cell Biol.
119, 629–641.
Chan, A.M., King, H.W., Deakin, E.A., Tempest, P.R., Hilkens, J.,
Kroezen, V., Edwards, D.R., Wills, A.J., Brookes, P. and Cooper, C.S.
(1988) “Characterization of the mouse met proto-oncogene”,
Oncogene 2, 593–599.
Danilkovitch-Miagkova, A., Miagkov, A., Skeel, A., Nakaigawa, N.,
Zbar, B. and Leonard, E.J. (2001) “Oncogenic mutants of RON and
MET receptor tyrosine kinases cause activation of the beta-catenin
pathway”, Mol. Cell Biol. 21, 5857–5868.
Di Renzo, M.F., Narsimhan, R.P., Olivero, M., Bretti, S., Giordano, S.,
Medico, E., Gaglia, P., Zara, P. and Comoglio, P.M. (1991)
“Expression of the Met/HGF receptor in normal and neoplastic
human tissues”, Oncogene 6, 1997–2003.
Ferrero,I.,Anjuere,F.,MacDonald,H.R.andArdavin,C.(1997)“Invitro
negative selection of viral superantigen-reactive thymocytes by
thymic dendritic cells”, Blood 90, 1943–1951.
Galimi, F., Bagnara, G.P., Bonsi, L., Cottone, E., Follenzi, A., Simeone,
A. and Comoglio, P.M. (1994) “Hepatocyte growth factor induces
proliferation and differentiation of multipotent and erythroid
hemopoietic progenitors”, J. Cell Biol. 127, 1743–1754.
Hu, Z., Evarts, R.P., Fujio, K., Marsden, E.R. and Thorgeirsson, S.S.
(1993) “Expression of hepatocyte growth factor and c-met genes
during hepatic differentiation and liver development in the rat”, Am.
J. Pathol. 142, 1823–1830.
Lee, W.P., Liao, Y., Robinson, D., Kung, H.J., Liu, E.T. and Hung, M.C.
(1999) “Axl-gas6 interaction counteracts E1A-mediated cell growth
suppression and proapoptotic activity”, Mol. Cell Biol. 19,
8075–8082.
Lin, W., Kao, H.W., Robinson, D., Kung, H.J., Wu, C.W. and Chen, H.C.
(2000) “Tyrosine kinases and gastric cancer”, Oncogene 19,
5680–5689.
Lu, Q. and Lemke, G. (2001) “Homeostatic regulation of the immune
system by receptor tyrosine kinases of the Tyro 3 family”, Science
293, 306–311.
Maina, F., Casagranda, F., Audero, E., Simeone, A., Comoglio, P.M.,
Klein, R. and Ponzetto, C. (1996) “Uncoupling of Grb2 from the Met
receptor in vivo reveals complex roles in muscle development”, Cell
87, 531–542.
Miura, H., Nishimura, K., Tsujimura, A., Matsumiya, K., Matsumoto, K.,
Nakamura, T. and Okuyama, A. (2001) “Effects of hepatocyte growth
factor on E-cadherin-mediated cell–cell adhesion in DU145 prostate
cancer cells”, Urology 58, 1064–1069.
Morino, N., Matsumoto, T., Ueki, K., Mimura, T., Hamasaki, K., Kanda,
H., Naruse, T., Yazaki, Y. and Nojima, Y. (1999) “Glomerular
overexpression and increased tyrosine phosphorylation of focal
adhesion kinase p125FAK in lupus-prone MRL/MP-lpr/lpr mice”,
Immunology 97, 634–640.
Nishino, T., Hisha, H., Nishino, N., Adachi, M. and Ikehara, S. (1995)
“Hepatocyte growth factor as a hematopoietic regulator”, Blood 85,
3093–3100.
Robinson, D., He, F., Pretlow, T. and Kung, H.J. (1996) “A tyrosine
kinase proﬁle of prostate carcinoma”, Proc. Natl Acad. Sci. USA 93,
5958–5962.
Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W.,
Sharpe, M., Gherardi, E. and Birchmeier, C. (1995) “Scatter
factor/hepatocyte growth factor is essential for liver development”,
Nature 373, 699–702.
Selden, C., Jones, M., Wade, D. and Hodgson, H. (1990) “Hepatotropin
mRNA expression in human foetal liver development and in liver
regeneration”, FEBS Lett. 270, 81–84.
Taguchi, N., Ansari, A., Hsu, T., Hashimoto, Y., Dorshkind, K., Shultz,
L., Naiki, M. and Gershwin, M.E. (2001) “Increased expression of
mXBP-1 (TREB-5) in thymic B cells in New Zealand mice”,
J. Autoimmun. 16, 401–410.
Taguchi, N., Hashimoto, Y., Hsu, T., Ansari, A.A., Shultz, L., Dorshkind,
K., Ikehara, S., Naiki, M. and Gershwin, M.E. (2001) “B cells are
selectively associated with thymic cortical but not medullary
pathology in NZB mice”, J. Autoimmun. 16, 393–400.
Takeoka, Y., Taguchi, N., Kotzin, B.L., Bennett, S., Vyse, T.J., Boyd,
R.L., Naiki, M., Konishi, J., Ansari, A.A., Shultz, L.D. and Gershwin,
M.E. (1999) “Thymic microenvironment and NZB mice: the
abnormal thymic microenvironment of New Zealand mice correlates
with immunopathology”, Clin. Immunol. 190, 388–398.
Tamura, S., Sugawara, T., Tokoro, Y., Taniguchi, H., Fukao, K.,
Nakauchi, H. and Takahama, Y. (1998) “Expression and function of
c-met, a receptor for hepatocyte growth factor, during T-cell
development”, Scand. J. Immunol. 47, 296–301.
Watanabe, Y., Naiki, M., Wilson, T., Godfrey, D., Chiang, B.L., Boyd, R.,
Ansari, A. and Gershwin, M.E. (1993) “Thymic microenvironmental
abnormalities and thymic selection in NZB.H-2bm12 mice”,
J. Immunol. 150, 4702–4712.
Xiao, G.H., Jeffers, M., Bellacosa, A., Mitsuuchi, Y., Vande Woude, G.F.
and Testa,J.R.(2001)“Anti-apoptotic signalingbyhepatocytegrowth
factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-
activated protein kinase pathways”, Proc. Natl Acad. Sci. USA 98,
247–252.
Yu, C.C., Yen, T.S., Lowell, C.A. and DeFranco, A.L. (2001) “Lupus-like
kidney disease in mice deﬁcient in the Src family tyrosine kinases
Lyn and Fyn”, Curr. Biol. 11, 34–38.
T. OKADA et al. 34